Karyopharm Therapeutics Stock Forecast, Price & News

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

Is Karyopharm Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Karyopharm Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares.
View analyst ratings for Karyopharm Therapeutics or view top-rated stocks.

How has Karyopharm Therapeutics' stock been impacted by Coronavirus?

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KPTI stock has decreased by 59.6% and is now trading at $8.58.
View which stocks have been most impacted by COVID-19.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Karyopharm Therapeutics.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The company had revenue of $37.69 million for the quarter, compared to analysts' expectations of $25.84 million. Karyopharm Therapeutics had a negative net margin of 173.81% and a negative trailing twelve-month return on equity of 7,204.16%. During the same period in the previous year, the firm earned ($0.73) EPS.
View Karyopharm Therapeutics' earnings history.

What price target have analysts set for KPTI?

7 brokers have issued 1-year price objectives for Karyopharm Therapeutics' stock. Their forecasts range from $8.00 to $26.00. On average, they expect Karyopharm Therapeutics' stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 78.7% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:

• Richard A. Paulson, President, CEO & Non-Executive Director
• Ronit Milstein, Vice President-Operations
• Mike Mason, Treasurer, Chief Financial & Accounting Officer
• Sharon Shacham, Chief Scientific Officer
• Yosef Landesman, Senior VP-Research & Translational Medicine

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees.

Who are some of Karyopharm Therapeutics' key competitors?

Some companies that are related to Karyopharm Therapeutics include Zentalis Pharmaceuticals (ZNTL), Insmed (INSM), Cytokinetics (CYTK), Emergent BioSolutions (EBS), Sage Therapeutics (SAGE), Arcus Biosciences (RCUS), Indivior (INVVY), I-Mab (IMAB), Nuvation Bio (NUVB), TG Therapeutics (TGTX), Aurinia Pharmaceuticals (AUPH), OPKO Health (OPK), EQRx (EQRX), Nektar Therapeutics (NKTR) and Corcept Therapeutics (CORT).
View all of KPTI's competitors.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (2.23%), Patriot Financial Group Insurance Agency LLC (0.05%) and Belvedere Trading LLC (0.00%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, Sharon Shacham, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends for Karyopharm Therapeutics.

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Patriot Financial Group Insurance Agency LLC, and Belvedere Trading LLC. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Garen G Bohlin, Jatin Shah, and John Demaree.
View insider buying and selling activity for Karyopharm Therapeutics or or view top insider-buying stocks.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $8.58.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics has a market capitalization of $648.19 million and generates $108.08 million in revenue each year. The company earns $-196.27 million in net income (profit) each year or ($2.76) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

Karyopharm Therapeutics employs 432 workers across the globe.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is www.karyopharm.com.

Where are Karyopharm Therapeutics' headquarters?

Karyopharm Therapeutics is headquartered at 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at (617) 658-0600 or via email at [email protected].